A patient arrives at the pharmacy and learns that a prescription needs authorization before it can be filled. The step is an insurance benefit review, and understanding it explains most of the delay.
The claim is checked against a formulary
Health plans maintain a list of covered drugs organized in tiers, with cost sharing that differs by tier and conditions attached to some entries.
When a pharmacy submits a claim, an automated system checks the drug against that list along with the patient's eligibility and any conditions.
A rejection code returned at this stage tells the pharmacy that coverage requires further review, which is what the counter staff relay to the patient.
Review conditions come in several forms
Prior authorization requires the prescriber to submit clinical information before coverage applies, typically documenting the diagnosis and prior treatments.
Step therapy requires that a preferred option be tried first, unless the prescriber documents a reason it is unsuitable.
Quantity limits cap the amount dispensed in a period, and exceeding them triggers a separate review even for a drug otherwise covered.
The prescriber's office does the work
The request is submitted by the clinician, not by the patient or the pharmacy, because the required information is clinical.
Electronic submission has shortened turnaround in many cases, though requests still queue behind other work in a busy practice.
Plans publish decision timeframes, with shorter windows for urgent requests where a delay could jeopardize a patient's condition.
Denials can be appealed
A denial is not the end of the process. Plans provide internal appeals, and many patients also have a right to external review by an independent entity.
The prescriber can usually request a peer-to-peer discussion with a plan reviewer, which resolves some cases faster than a written appeal.
Rights and deadlines depend on the type of plan and on state law, so the plan documents and the state insurance regulator are the accurate sources.
Why the process exists and what it costs
Insurers describe these controls as tools for steering toward equally effective lower-cost options and for limiting use outside approved indications.
Clinicians point to administrative burden and to treatment delays, and several states have passed laws narrowing when reviews may be required.
A patient facing an interruption in an ongoing medication should contact the prescribing clinician promptly rather than stopping or rationing a treatment on their own.